VBI Vaccines Inc.: VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

Presentation title: "Long-Term Persistence of Anti-HBs Antibodies after Vaccination with a 3-Antigen HBV Vaccine Compared with a Single-Antigen HBV Vaccine" VBI Vaccines Inc. (Nasdaq: VBIV) (VBI)

Related Keywords

United States ,United Kingdom ,Israel ,Massachusetts ,Finland ,Cambridge ,Cambridgeshire ,Canada ,Rehovot ,Hamerkaz ,Ottawa ,Ontario ,America ,Canadian ,Francisco Diaz Mitoma ,Nicole Anderson ,Timo Vesikari ,Prehevbrio Prehevbri ,Vaccines Inc ,Company Quarterly Reports On Form ,Nasdaq ,European Union Economic Area ,Corporate Communications ,Nordic Vaccine Research Network ,International Liver Congress ,Term Persistence ,Annual Meeting ,European Association ,Professor Emeritus ,North America ,Follow Up Study ,Follow Up Analysis ,European Economic Area ,Safety Information ,European Summary ,Product Characteristics ,Full Prescribing ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Vaccines ,Nnounces ,Song ,Term ,Follow ,Linical ,Data ,Ntigen ,Adult ,Hepatitis ,Vaccine ,Resented ,Asl ,022 ,